Steve Kirsch on Gab: "In January, after a Key Opinion Leader (KOL) panel of experts from FDA, NIH, CDC, academia, and journals **voted more than 2 to 1 to recommend fluvoxamine**, I ..."

Steve Kirsch on Gab: "In January, after a Key Opinion Leader (KOL) panel of experts from FDA, NIH, CDC, academia, and journals **voted more than 2 to 1 to recommend fluvoxamine**, I ..."